Trending Stock News

Stemline Therapeutics, Inc. (STML) Forms $13.45 Double Top; BSB Bancorp Has 1.16 Sentiment

Stemline Therapeutics, Inc. (STML) formed double top with $14.66 target or 9.00% above today’s $13.45 share price. Stemline Therapeutics, Inc. (STML) has $340.11 million valuation. The stock decreased 4.61% or $0.65 during the last trading session, reaching $13.45. About 135,006 shares traded. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 52.65% since January 17, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

BSB Bancorp, Inc. operates as the holding firm for Belmont Savings Bank that provides commercial and retail banking services to small businesses, municipalities, and other clients in the United States. The company has market cap of $297.27 million. The Company’s deposit products include relationship checking accounts for clients and businesses, passbook and statement savings accounts, certificates of deposit, money market accounts, interest on lawyer trust accounts, and individual retirement accounts, as well as commercial, municipal, and regular checking accounts. It has a 18.09 P/E ratio. The companyÂ’s loan portfolio comprises one to four family residential mortgage loans, commercial real estate loans, multi-family real estate loans, home equity lines of credit, indirect automobile loans, commercial business loans, construction loans, other consumer loans, and second mortgage loans.

The stock increased 0.82% or $0.25 during the last trading session, reaching $30.6. About 10,111 shares traded or 3.13% up from the average. BSB Bancorp, Inc. (BLMT) has risen 33.12% since January 17, 2017 and is uptrending. It has outperformed by 16.42% the S&P500.

Clover Partners L.P. holds 3.67% of its portfolio in BSB Bancorp, Inc. for 305,547 shares. Fj Capital Management Llc owns 422,000 shares or 1.53% of their US portfolio. Moreover, Banc Funds Co Llc has 1.26% invested in the company for 936,460 shares. The Minnesota-based Punch & Associates Investment Management Inc. has invested 0.52% in the stock. Prospector Partners Llc, a Connecticut-based fund reported 60,000 shares.

Analysts await Stemline Therapeutics, Inc. (NASDAQ:STML) to report earnings on March, 15. They expect $-0.67 earnings per share, down 19.64% or $0.11 from last year’s $-0.56 per share. After $-0.68 actual earnings per share reported by Stemline Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -1.47% EPS growth.

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc has $38.0 highest and $11 lowest target. $24.25’s average target is 80.30% above currents $13.45 stock price. Stemline Therapeutics Inc had 12 analyst reports since November 10, 2015 according to SRatingsIntel. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) earned “Buy” rating by H.C. Wainwright on Thursday, December 14. The stock has “Buy” rating by Cowen & Co on Friday, June 23. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 1 report. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) has “Buy” rating given on Friday, November 10 by H.C. Wainwright. The rating was maintained by Wedbush on Monday, February 6 with “Outperform”. The rating was maintained by Cowen & Co with “Buy” on Wednesday, June 14. H.C. Wainwright maintained the shares of STML in report on Monday, June 26 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $3400 target in Wednesday, August 9 report. H.C. Wainwright maintained Stemline Therapeutics, Inc. (NASDAQ:STML) on Tuesday, September 12 with “Buy” rating. Jefferies maintained it with “Buy” rating and $1600 target in Monday, June 26 report.

Since December 15, 2017, it had 0 insider buys, and 2 selling transactions for $365,519 activity. Hoberman Kenneth sold $195,577 worth of Stemline Therapeutics, Inc. (NASDAQ:STML) on Monday, January 8.

Investors sentiment increased to 1.24 in Q3 2017. Its up 0.24, from 1 in 2017Q2. It increased, as 6 investors sold Stemline Therapeutics, Inc. shares while 19 reduced holdings. 13 funds opened positions while 18 raised stakes. 12.54 million shares or 4.36% more from 12.02 million shares in 2017Q2 were reported. Wells Fargo Commerce Mn owns 15,020 shares. Baker Bros Lp invested in 633,497 shares. Balyasny Asset Mgmt Lc stated it has 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Edge Wealth Management Limited Liability Company holds 0% in Stemline Therapeutics, Inc. (NASDAQ:STML) or 500 shares. Fmr Ltd Co invested in 0% or 2.00M shares. Susquehanna Group Llp holds 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 25,914 shares. Comml Bank Of America Corporation De stated it has 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Axa holds 620,546 shares or 0.03% of its portfolio. Deutsche Bancshares Ag accumulated 194,146 shares or 0% of the stock. Voya Management Ltd Liability reported 0% stake. Citigroup Inc holds 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 70 shares. 40,200 were accumulated by Schwab Charles Mgmt. Morgan Stanley stated it has 30,213 shares or 0% of all its holdings. D E Shaw & Company has invested 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). J Goldman And Limited Partnership invested in 101,316 shares or 0.06% of the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *